Perfluorocarbon (ABL-101) Oxygenation for Stroke: Trial With GOLD (Glasgow Oxygen Level Dependent Technology) Imaging Theranostic

Inclusion Criteria: * Aged ≥18 years. * Males or females not of child-bearing potential defined as being post-menopausal based on cessation of regular menses for a minimum of 12 consecutive months with no alternative cause, permanently sterilised (e.g. hysterectomy, bilateral tubal occlusion, bilateral salpingectomy), or having medically confirmed ovarian failure. * Ischaemic stroke \<72h after onset. * Previous functional independence (estimated mRS \<3). * Capacity to consent. Exclusion Criteria: * Women of child bearing potential. * Contraindications to MRI scanning (eg cardiac pacemaker, ferromagnetic implants, known hypersensitivity to gadolinium containing contrast media). * Known allergy to ABL-101 or any of its constituents, (including egg phospholipids). * Clinical need for, or contraindication to, supplemental oxygen. * Known impaired renal function (eGFR \<30ml/min) precluding radiological contrast. * Known thrombocytopaenia (platelet count \<150x109) or history of platelet function disorder. * Known intercurrent infection. * Known severe COPD or cardiac failure (eg significantly limiting exercise capacity or requiring hospitalisation within the preceding 12 months). * Known significant liver disease (eg liver failure or cirrhosis, chronic infectious or autoimmune hepatitis, or transaminases \>3 times upper limit of normal). * Any current medical condition causing impaired immunity (eg HIV infection, hyposplenism) or use of systemic immunosuppressant medication except for inhaled, nasal intra-articular or topical corticosteroids) on an ongoing basis or within the preceding 30 days. * Any medical condition potentially limiting survival within the study follow-up period. * Participation in another CTIMP within preceding 90 days.